OS01.5 Development of TERT-targeting therapy using eribulin mesylate in mouse glioblastoma model

Introduction: Despite of recent extensive genome analysis, no effective molecular targeting therapy has been successfully developed in patients with glioblastomas (GBMs). Approximately 60–80% of GBM harbour mutations in the promoter region of telomerase reverse transcriptase (TERT) that leads to upr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Takahashi, M., Miki, S., Fukuoka, K., Yasukawa, M., Hayashi, M., Hamada, A., Mukasa, A., Nishikawa, R., Tamura, K., Narita, Y., Masutomi, K., Ichimura, K.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2017
Ämnen:
ORAL PRESENTATIONS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463620/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.004
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk